Local view for "http://purl.org/linkedpolitics/eu/plenary/2009-03-23-Speech-1-128"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2009-03-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:The placing of biocidal products on the market – New biocides revision proposal (debate)2
dcterms:Language	"pl"^^xsd:language2
lpv:document identification number	"en.20090323.16.1-128"2
lpv:hasSubsequent	lp_eu:2009-03-23-Speech-1-1292
lpv:speaker	lp:Urszula Krupa2
lpv:spokenAs	member; Delegation for relations with Canada (2007-03-15--2009-07-13)3 member; ENVI (2007-01-31--2009-07-13)3 member; FEMM (2007-01-31--2009-07-13)3 member_of_the_bureau; IND/DEM (2007-02-13--2009-07-13)3 unknown; - (2006-06-14--2009-07-13)3 substitute; AFCO (2007-01-31--2009-07-13)3 member; Delegation for relations with South Africa (2007-03-14--2009-07-13)3
lpv:translated text	". Mr President, harmonising the legislation on biocidal products in the European Union seems all the more necessary given that regulations in specific countries are very varied. The lack of common legislative provisions poses a danger to people’s health and lives, as well as being an environmental threat, especially under free market conditions. However, the proposal contained in the initial version of the text, namely a ten-year implementation period for the legislation, seems to be unrealistic, in view of the extremely complicated and expensive registration procedures for the chemicals used in these products. These procedures, which were intended to ensure a high level of safety, could, ironically enough, contribute to reducing the level of control, which is all the more problematic if we consider the fact that, in some cases, national regulations controlled the biocidal products introduced onto the market. However, removing these mechanisms and introducing less efficient and expensive assessment procedures may restrict the sales of biocidal products. A central, European register of active substances used in biocidal products will not ensure safety, either, especially in view of the fact that biological agents are extremely variable and are resistant to active agents. Having a limited choice of effective compounds will only serve to increase resistance levels. Moreover, the high costs and complicated procedures involved will push small companies out of the market, leading to the market becoming monopolised by large companies working in this sector. The proposal to have an extended, 14-year transitional period, which could be extended by another two years, has become all the more invaluable due to the fact that it will not be possible to register active substances or transpose these regulations into national law before 2014."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph